Husseini Manji

, MD

Global Head, Johnson & Johnson Science for Minds

Husseini K. Manji, MD, FRCPC is Global Head, Johnson & Johnson (J&J) Science for Minds. He previously was Global Therapeutic Head for Neuroscience at Janssen R&D, LLC, a J&J pharmaceutical company. Before joining J&J, Dr. Manji was Chief of the Laboratory of Molecular Pathophysiology at the National Institutes of Health (NIH) and Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. Dr. Manji’s research has helped to conceptualize neuropsychiatric disorders as genetically influenced disorders of synapses and circuits and has prompted the investigation of novel therapeutics for refractory patients. His work led to the FDA, Canada and EC approval of the first novel antidepressant mechanism in decades, SPRAVATO® (esketamine) nasal spray for adults with treatment-resistant major depressive disorder. Dr. Manji has received numerous prestigious awards, is Visiting Professor at Duke University, Honorary Fellow at Oxford University, member of the World Dementia Council, member of the Scientific Advisory Board of the Stanley Center at the Broad Institute of MIT and Harvard, and member of the World Economic Forum, Global Futures Council.

Read more

This Speaker's Sessions

Town Hall
Tuesday Oct. 20
2:00 PM
ET
Watch Replay
Now Live!

On the Path to 2025: Treatments and Diagnostics to Change the Trajectory of the Disease

What are the latest innovations in the drug pipeline?  How important is the need to develop diagnostics that can improve diagnosis and draw more patients into clinical trials, especially patients at high risk of Alzheimer’s? The panel will underscore the critical importance of progress on detection, diagnosis, research and treatments to stop Alzheimer’s. Key question: Will the U.S. meet our national goal of preventing and effectively treating Alzheimer's disease by 2025?

View SessionWatch Replay